The sporadic transition from indolent to metastatic disease is a hallmark of prostate cancer (PC) and frequently involves deletion of PTEN and TP53. We recently recapitulated metastasis of Pten/ Trp53-mutant PC in mouse using the RapidCaP system and surprisingly, we found that it is driven by Myc, rather than Akt activation. Here, we show that cell-cell communication by Il6 drives this Akt-Myc switch through activation of the Akt-inactivating phosphatase Phlpp2. Primary cells revealed that loss of Pten/ Trp53 triggers secretion of the Il6 cytokine when these genes are deleted together, but not separately. Il6 then communicates a downstream program of Stat3-mediated Myc activation, which drives cell proliferation. Abrogation of Myc activi...
The transcript encoding the proto-oncogene MYC is commonly overexpressed in prostate cancer (PC). MY...
Metastatic prostate cancer commonly presents with targeted, bi-allelic mutations of the PTEN and TP5...
The transcript encoding the proto-oncogene MYC is commonly overexpressed in prostate cancer (PC). MY...
We have recently recapitulated metastasis of human PTEN/TP53-mutant prostate cancer in the mouse usi...
We have recently recapitulated metastasis of human PTEN/TP53-mutant prostate cancer in the mouse usi...
We have recently recapitulated metastasis of human PTEN/ TP53-mutant PC in mouse using the RapidCaP ...
Genetically Engineered Mouse (GEM) models are a pillar of functional cancer research. Here we develo...
PTEN loss stimulates prostate tumor progression by sustaining AKT activation. Nowak et al. (2019. J....
Metastasis is a major driver of mortality and morbidity in prostate cancer, the most common cancer t...
MYC and phosphoinositide 3-kinase (PI3K)-pathway deregulation are common in human prostate cancer. T...
MYC and phosphoinositide 3-kinase (PI3K)-pathway deregulation are common in human prostate cancer. T...
MYC and phosphoinositide 3-kinase (PI3K)-pathway deregulation are common in human prostate cancer. T...
SummaryHyperactivation of the PI 3-kinase/AKT pathway is a driving force of many cancers. Here we id...
Hyperactivation of the PI 3-kinase/AKT pathway is a driving force of many cancers. Here we identify ...
SummaryHyperactivation of the PI 3-kinase/AKT pathway is a driving force of many cancers. Here we id...
The transcript encoding the proto-oncogene MYC is commonly overexpressed in prostate cancer (PC). MY...
Metastatic prostate cancer commonly presents with targeted, bi-allelic mutations of the PTEN and TP5...
The transcript encoding the proto-oncogene MYC is commonly overexpressed in prostate cancer (PC). MY...
We have recently recapitulated metastasis of human PTEN/TP53-mutant prostate cancer in the mouse usi...
We have recently recapitulated metastasis of human PTEN/TP53-mutant prostate cancer in the mouse usi...
We have recently recapitulated metastasis of human PTEN/ TP53-mutant PC in mouse using the RapidCaP ...
Genetically Engineered Mouse (GEM) models are a pillar of functional cancer research. Here we develo...
PTEN loss stimulates prostate tumor progression by sustaining AKT activation. Nowak et al. (2019. J....
Metastasis is a major driver of mortality and morbidity in prostate cancer, the most common cancer t...
MYC and phosphoinositide 3-kinase (PI3K)-pathway deregulation are common in human prostate cancer. T...
MYC and phosphoinositide 3-kinase (PI3K)-pathway deregulation are common in human prostate cancer. T...
MYC and phosphoinositide 3-kinase (PI3K)-pathway deregulation are common in human prostate cancer. T...
SummaryHyperactivation of the PI 3-kinase/AKT pathway is a driving force of many cancers. Here we id...
Hyperactivation of the PI 3-kinase/AKT pathway is a driving force of many cancers. Here we identify ...
SummaryHyperactivation of the PI 3-kinase/AKT pathway is a driving force of many cancers. Here we id...
The transcript encoding the proto-oncogene MYC is commonly overexpressed in prostate cancer (PC). MY...
Metastatic prostate cancer commonly presents with targeted, bi-allelic mutations of the PTEN and TP5...
The transcript encoding the proto-oncogene MYC is commonly overexpressed in prostate cancer (PC). MY...